Publications

5808 Results

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Authors
J Amengual;P Reagan;H Li;T Al Baghdadi;H Saeed;R Vaidya;J Unger;A Danilov;M LeBlanc;JW Friedberg;S Smith
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Lymphoma
Study Number(s)
S2207

Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

Authors
V Liu;M Othus;R Ries;J Neru;E Pogosova-Agadjanyan;F Appelbaum;L Beppu;T Chauncey;H Erba;J Godwin;M Fitzgibbon;M Fang;A Moseley;J Radich;C Willman;F Wu;S Meshinchi;D Stirewalt
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Leukemia

Representation of Minorities in Therapeutic Clinical Trials – A 15-Year Review of Lymphoma Cooperative Group Studies

Authors
A Alencar;E Paskett;S Geyer;L Pederson;T Dokter;N Ghosh;K Adekola;J Unger;O Jegede;J Friedberg;B Kahl;S Dinner;N Bartlett;K Blum;J Leonard
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), oral
Year
2024
Research Committee(s)
Cancer Care Delivery and Lymphoma

Consent to Future Use of Residual and Banked Specimens among Adults with Hematologic Malignancies: Analyzing SWOG Clinical Trial Data from 2000-2024

Authors
D Olivieri;A Berridge-Green;M Othus;J Radich;A Advani;H Erba;R Walter
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Leukemia

The Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Adult Patients with B-cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Trial

Authors
D DeAngelo;V Yin;A Advani;S Lugar;J Fulcher;M Liedtke;G Uy;S Dinner;L Wilde;H Erba;M Litzow;R Stone;P Mohindra;J Bogart;W Stock
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), oral
Year
2024
Research Committee(s)
Leukemia

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Authors
J Altman;Sun;Perl;Little;Gore;L Michaelis;G Uy;Y Abaza;Abedin;Reagan;Atallah;Luger;M Litzow
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Leukemia
Study Number(s)
MYELOMATCH

A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Authors
S Ailawadhi;A Hoering;JC Ye;B Lipe;D Calverley;T Chauncey;K Gowin;S Holstein;E Campagnaro;V Rajkumar;S Usmani;A Rosenthal;J Aiello;R Orlowski
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Myeloma
Study Number(s)
S2209

Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Authors
N Podoltsev;Z Sun;M Litzow;E Paietta;K Roberts;Y Xhang;J Racevckis;H Lazarus;J Rowe;D Arber;M Wieduwilt;M Liedtke;J Bergeron;B Wood;Y Zhao;G Wu;T Chang;W Zhang;K Pratz;S Dinner;N Frey;S Gore;B Bhatnagar;E Atallah;G Uy;D Jeyakumar;T Lin;C Willman;D De Angelo;S Patel;M Elliott;A Advani;D Tzachanis;P Vachhani;R Bhave;E Sharon;R Little;H Erba;R Stone;C Mullighan;M Tallman;S Luger;R Mattison
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Leukemia
Study Number(s)
CTSU/E1910

Assessment of Outcomes of Allogeneic Stem Cell Transplantation by Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial

Authors
M Liedtke;Z Sun;M Litzow;R Mattison;E Paietta;K Roberts;Y Zhang;J Racevckis;H Lazarus;J Rowe;D Arber;J Bergeron;B Wood;Y Zhao;G Wu;T Chang;W Zhang;K Pratz;S Dinner;N Frey;S Gore;B Bhatnagar;E Atallah;G Uy;D Jeyakumar;T Lin;C Willman;D DeAngelo;S Patel;M Elliott;A Advani;D Tzachanis;P Vachhani;R Bhave;E Sharon;R Little;H Erba;R Stone;C Mullighan;M Tallman;S Luger;M Wieduwilt
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), oral
Year
2024
Research Committee(s)
Leukemia
Study Number(s)
CTSU/E1910

Reexamining NCTN Clinical Trials for Sex Differences in Outcomes and Toxicities in Patients with Neuroendocrine Neoplasms

Authors
W Tan;L Cramer;N Vijayvergia;M Lustberg;M Kulke;J Yao;P Kunz
Journal / Conference
NANETS Symposium (North American Neuroendocrine Tumor Society (Nov 21-23, 2024, Chicago, IL), poster
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80701, CTSU/E2211, S0518